# SynapDx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synapdx

- Industry: Medical Devices & Equipment
- Headquarters: Southborough, US
- Website: www.synapdx.com
- Total disclosed funding: $31M
- Latest round: Series A (Jul 22, 2013)
- Investors on record: 5

## About

SynapDx Corp is a biotechnology company focused on developing innovative solutions for health diagnostics and therapeutic interventions. Their pioneering efforts aim to advance healthcare through advanced research and product offerings in the realm of human growth hormone.SynapDx Corp specializes in health diagnostics and therapeutic solutions. The company was founded in Southborough, US, and has undergone strategic pivots to enhance its focus on innovative health products. The firm was established by a team of professionals with relevant industry experience. SynapDx has successfully raised USD 15.35 mn in Series A funding in July 2013, led by GV, with participation from Foundation Medical Partners, General Catalyst Partners, and North Bridge Venture Partners. The total amount raised by the company to date stands at USD 15.35 mn, and its current valuation is USD 32.52 mn.SynapDx specializes in the sale of human growth hormone (HGH) products, catering to a diverse customer base that includes athletes, fitness enthusiasts, and individuals seeking anti-aging benefits. The company's core offerings consist of injectable HGH from reputable brands such as Genotropin, Zptropin, and Norditropin, all of which are lab-tested and verified for safety and effectiveness. These products aim to enhance energy levels, improve physical performance, facilitate recovery, and promote overall vitality. SynapDx markets its products primarily in North America and Europe, ensuring that customers have access to quality HGH options that meet pharmaceutical standards. The company places a strong emphasis on transparency and quality, positioning itself as a reliable source for both high-end and affordable HGH solutions.SynapDx generates revenue through direct-to-consumer sales of its HGH products, structured as individual transactions that involve one-time purchases rather than subscriptions or recurring payments. The pricing model reflects real value, making high-quality HGH accessible to a broader audience. Customers engage with SynapDx by selecting from a variety of HGH products that vary in price based on brand and formulation, allowing for tailored purchasing decisions according to individual needs and budgets. The company’s commitment to providing lab-tested and verified products fosters customer trust and satisfaction, which is pivotal in driving repeat business and maintaining a strong market presence in the HGH sector.SynapDx plans to leverage its recent funding of USD 15.35 mn from the Series A round to support the development of new growth hormone products and expand its market reach. The company is targeting new geographic regions, specifically Asia and South America, potentially by 2025, to broaden its customer base. The funds raised will be crucial in facilitating the launch of innovative products designed to meet diverse consumer needs and improve accessibility in these emerging markets.

## Funding rounds

- Series A, Jul 22, 2013, $15M — General Catalyst Partners, North Bridge Venture Partners, Foundation Medical Partners, GV
- Series A, Dec 11, 2012, $6M — General Catalyst Partners, North Bridge Venture Partners
- Series A, May 26, 2010, $9.3M — Bain Capital, General Catalyst Partners, North Bridge Venture Partners

## Investors

- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series A
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series A
- North Bridge Venture Partners (https://capitalatlas.ai/funds/north-bridge-venture-partners) — Series A
- Foundation Medical Partners (https://capitalatlas.ai/funds/foundation-medical-partners) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A